BR112013020969A2 - proteínas de membrana solúvel em água e métodos para a sua preparação e uso. - Google Patents

proteínas de membrana solúvel em água e métodos para a sua preparação e uso.

Info

Publication number
BR112013020969A2
BR112013020969A2 BR112013020969A BR112013020969A BR112013020969A2 BR 112013020969 A2 BR112013020969 A2 BR 112013020969A2 BR 112013020969 A BR112013020969 A BR 112013020969A BR 112013020969 A BR112013020969 A BR 112013020969A BR 112013020969 A2 BR112013020969 A2 BR 112013020969A2
Authority
BR
Brazil
Prior art keywords
preparation
methods
water
membrane proteins
soluble membrane
Prior art date
Application number
BR112013020969A
Other languages
English (en)
Portuguese (pt)
Inventor
Rich Alexander
Corin Karolina
T Tegler Lotta
Zhang Shuguang
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BR112013020969A2 publication Critical patent/BR112013020969A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
BR112013020969A 2011-02-23 2012-02-23 proteínas de membrana solúvel em água e métodos para a sua preparação e uso. BR112013020969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445740P 2011-02-23 2011-02-23
PCT/US2012/026353 WO2012116203A1 (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
BR112013020969A2 true BR112013020969A2 (pt) 2018-07-10

Family

ID=46721234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020969A BR112013020969A2 (pt) 2011-02-23 2012-02-23 proteínas de membrana solúvel em água e métodos para a sua preparação e uso.

Country Status (14)

Country Link
US (4) US8637452B2 (https=)
EP (1) EP2709647B1 (https=)
JP (1) JP6263773B2 (https=)
KR (1) KR101963914B1 (https=)
CN (2) CN108752461A (https=)
AU (3) AU2012220558A1 (https=)
BR (1) BR112013020969A2 (https=)
CA (1) CA2827187C (https=)
CL (1) CL2013002419A1 (https=)
EA (1) EA201391041A1 (https=)
IL (2) IL227886A0 (https=)
MX (1) MX347038B (https=)
SG (2) SG10201701547VA (https=)
WO (1) WO2012116203A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201701547VA (en) 2011-02-23 2017-03-30 Massachusetts Inst Technology Water soluble membrane proteins and methods for the preparation and use thereof
EP2968135A4 (en) 2013-03-14 2016-10-26 Massachusetts Inst Technology INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES
WO2014176544A1 (en) * 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Water soluble g-protein coupled receptor
WO2014176524A2 (en) 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
GB2527286A (en) * 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
CN104198689A (zh) * 2014-08-25 2014-12-10 李洁 一种检测g-蛋白耦联受体对缩血管物质反应的方法
JP7061461B2 (ja) * 2015-02-18 2022-04-28 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜貫通タンパク質ならびにその調製および使用方法
CN104946674B (zh) * 2015-06-17 2018-05-01 山东大学 一种腺苷三磷酸/双磷酸酶及其编码基因与应用
CN106749602A (zh) * 2016-12-30 2017-05-31 武汉金开瑞生物工程有限公司 一种助表达序列及其在无细胞表达adcy2蛋白中的应用
WO2019046699A1 (en) * 2017-09-01 2019-03-07 Massachustetts Institute Of Technology NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF
JP7250283B2 (ja) * 2017-12-11 2023-04-03 アステラス製薬株式会社 細胞膜透過性ペプチド
CN108245686B (zh) * 2018-01-15 2019-08-13 中国科学院昆明动物研究所 人grk5基因的用途
WO2021195177A1 (en) * 2020-03-25 2021-09-30 Massachusetts Institute Of Technology Qty fc fusion water soluble receptor proteins
WO2021202186A2 (en) 2020-03-31 2021-10-07 Massachusetts Institute Of Technology Qty fc fusion receptor proteins
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544021A (en) * 1895-08-06 William k
NZ240718A (en) 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5739273A (en) * 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
JPH09278793A (ja) * 1996-04-10 1997-10-28 Kinichiro Miura ポリペプチド
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CN1350544A (zh) * 1999-03-11 2002-05-22 格莱风科学公司 可溶性膜蛋白受体结构域的化学合成及应用
CA2400214A1 (en) 2000-02-11 2001-11-15 Amgen Inc. Fusion receptor from tnf family
US20030143668A1 (en) * 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
EP1593060A2 (en) 2003-01-21 2005-11-09 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
EP1789452B1 (en) 2004-08-25 2012-04-25 Janssen Pharmaceutica NV Relaxin-chimeric polypeptides and their preparation and use
KR20070112155A (ko) * 2005-02-08 2007-11-22 리서치 디벨럽먼트 파운데이션 가용성 Ｇ-단백질 연결 수용체(ｓＧＰＣＲ)와 관련된조성물 및 방법
BRPI0502759B1 (pt) * 2005-06-30 2014-02-25 óleo lubrificante e composição lubrificante para uma máquina de refrigeração
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
DK2121919T3 (da) 2007-03-22 2012-05-21 Heptares Therapeutics Ltd Mutante g-proteinkoblede receptorer og fremgangsmåder til udvælgelse heraf
US20100249022A1 (en) 2007-05-18 2010-09-30 University Of Massachusetts Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
SI2531492T1 (sl) 2010-02-05 2016-08-31 Heptares Therapeutics Limited Derivati 1,2,4-triazin-4-amina
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
SG10201701547VA (en) 2011-02-23 2017-03-30 Massachusetts Inst Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US20130273585A1 (en) 2012-04-11 2013-10-17 Gangagen, Inc. Soluble cytoplasmic expression of heterologous proteins in escherichia coli
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof

Also Published As

Publication number Publication date
CL2013002419A1 (es) 2014-06-06
AU2016201914A1 (en) 2016-04-21
MX2013009715A (es) 2014-02-28
US20140243277A1 (en) 2014-08-28
EA201391041A1 (ru) 2014-04-30
US9309302B2 (en) 2016-04-12
EP2709647B1 (en) 2019-08-07
CA2827187A1 (en) 2012-08-30
US20180312562A1 (en) 2018-11-01
WO2012116203A1 (en) 2012-08-30
EP2709647A4 (en) 2015-01-21
MX347038B (es) 2017-04-10
SG10201701547VA (en) 2017-03-30
JP6263773B2 (ja) 2018-01-24
AU2012220558A1 (en) 2013-08-22
CN103458915A (zh) 2013-12-18
US20120252719A1 (en) 2012-10-04
CA2827187C (en) 2019-01-08
IL261151A (en) 2018-10-31
SG192646A1 (en) 2013-09-30
EP2709647A1 (en) 2014-03-26
US10035837B2 (en) 2018-07-31
CN108752461A (zh) 2018-11-06
JP2014508763A (ja) 2014-04-10
IL227886A0 (en) 2013-09-30
US8637452B2 (en) 2014-01-28
AU2017261525A1 (en) 2017-12-07
US20160264640A1 (en) 2016-09-15
KR101963914B1 (ko) 2019-03-29
KR20140027117A (ko) 2014-03-06

Similar Documents

Publication Publication Date Title
BR112013020969A2 (pt) proteínas de membrana solúvel em água e métodos para a sua preparação e uso.
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
PT2784157T (pt) Método para conceber proteínas de ligação a rna usando o motivo ppr e sua utilização
BR112013018656A2 (pt) sistemas e métodos para maximização de uso de amostra
PT2726092T (pt) Polipéptidos de fusão serpina e métodos para a sua utilização
BR112014024676A2 (pt) Adsorvedor de iodeto de metila, sua utilização e método para a adsorção de iodeto de metila.
BR112014007789A2 (pt) sistemas e métodos para análise biológica
BR112014005744A2 (pt) composições de peptídeo glucagon-like-2 e métodos para sua produção e utilização
EP2673901A4 (en) NANOMECHANICAL TEST SYSTEM
BR112013029203A2 (pt) método para a preparação de um ou mais oligossacarídeos de leite humano, e, uso de oligossacarídeos de leite humano
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
BRPI1012924A2 (pt) derivados de amilóide p de soro e sua preparação e uso.
BR112013006092A2 (pt) laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado
BR112012004297A2 (pt) concentrado perolado e método para a fabricação do mesmo.
BR112014008088A2 (pt) método para detectar anticorpos, uso de um método, e, kit
BR112013030886A2 (pt) método, reagente e kit para medir hemoglobina glicada.
BR112012016229A2 (pt) método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab
BR112012000110A2 (pt) sistema de fornecimento de sabor em partículas, método para a sua fabricação e o uso do mesmo
BR112014009178A2 (pt) métodos, uso, receptor e invenção
EP2755269A4 (en) cogeneration
BR112013032690A2 (pt) método para produzir um composto, composto, e, uso do mesmo
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
EP2669499A4 (en) cogeneration
BR112013028894A2 (pt) composto de tiazol, métodos para preparação e uso do mesmo
BR112013015083A2 (pt) sistema para uso com um poço

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements